Health TrialsbyHealthPanel

Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases

ConditionsPhenotypic Age AccelerationBiological Aging MarkerMortality Risk PredictionDisease Risk PredictionLife ExpectancyDisease-Free HealthspanChinese PopulationObservational Cohort Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age35+
SponsorSecond Affiliated Hospital of Nanchang University

About this trial

The goal of this observational study is to learn about the ability of Phenotypic Age Acceleration (PhenoAgeAccel) to predict four key health outcomes in Chinese people with or at risk of major chronic diseases: the risk of developing new chronic diseases, the risk of dying, life expectancy, and disease-free healthspan.

The main questions this study aims to answer are:

* Does higher PhenoAgeAccel increase the risk of developing major chronic diseases (including diabetes, dementia, cancer, and chronic respiratory diseases) in Chinese adults? * Does higher PhenoAgeAccel increase the risk of death from all causes in Chinese adults? * How do life expectancy and disease-free healthspan differ between people with high versus low PhenoAgeAccel?

Who can take part in this study? Adults aged 35 or above years old who receive routine care at participating hospitals in China, have complete routine blood test data available, and have provided consent to use their health information for research purposes.

What will participants go through? Participants will receive their usual medical care as they normally would. No new treatments, tests, or procedures will be performed specifically for this study. We will collect data from their medical records, including blood test results used to calculate PhenoAgeAccel, diagnoses of new diseases, and dates of death.

What are the potential benefits? Participants will not receive direct personal benefits from taking part in this study. However, the information learned may help us better understand biological aging and improve future risk assessment and health management for people with chronic diseases.

Is this study safe? Yes. This is an observational study that does not involve any new drugs, devices, or invasive procedures. All data used in the study will be de-identified and kept strictly confidential to protect participants' privacy.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adults aged 35-73 years old. Complete routine blood test data available at baseline to calculate Phenotypic -Age (including albumin, alkaline phosphatase, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean corpuscular volume, red cell distribution width, and white blood cell count).

Consent to use routine medical data for research follow-up analysis.

Disqualifiers

Presence of end-stage diseases (e.g., end-stage liver/renal failure) other than the major chronic diseases of interest at baseline.

Key baseline data missing, making Phenotypic Age calculation impossible. Incomplete follow-up information or inability to confirm outcomes (e.g., death, disease onset) via database linkage.

Refusal to participate in the study or withdrawal of informed consent.

Trial population

The study population consists of Chinese adults aged 35-73 years from multicenter clinical cohorts in northern and southern China, with complete routine blood test data available at baseline. All participants are patients receiving routine care at collaborating hospitals. Data are prospectively collected via electronic medical records to analyze the association between Phenotypic Age Acceleration and major chronic disease and mortality outcomes.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • No Intervention (Observational Study)

    Other intervention

    This is an observational study with no study-specific intervention. All participants receive their routine standard medical care as usual. No new drugs, devices, procedures, or behavioral modifications are assigned as part of this research.

Treatment groups

2,000,000 Participants
are divided into 3 treatment groups
Group A: Non-accelerated PhenoAge Group1 intervention
Group B: Mildly Accelerated PhenoAge Group1 intervention
Group C: Severely Accelerated PhenoAge Group1 intervention

Trial outcomes

Primary outcomes

1

Incidence of Major Chronic Diseases

Composite incidence of new-onset major chronic diseases, including type 2 diabetes, dementia, cancer, and chronic respiratory diseases, defined by ICD-10 codes from electronic medical records.

Time frame
Baseline through study completion, average 10 years
2

All-Cause Mortality

All-cause mortality, defined as death from any cause, identified through linkage with death registration databases.

Time frame
Baseline through study completion, average 10 years

Secondary outcomes

1

Life Expectancy

Estimated remaining life expectancy stratified by biological aging status (PhenoAgeAccel) using parametric survival models.

Time frame
Baseline through study completion, average 10 years
2

Disease-Free Healthspan

Estimated years of life free from major chronic diseases, calculated as the difference between life expectancy and time spent with chronic diseases

Time frame
Baseline through study completion, average 10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Second Affiliated Hospital of Nanchang University

Lead sponsor

Source ClinicalTrials.gov
Apply now